Bristol Myers Squibb Co (NYSE:BMY) is significantly upgrading its computational capabilities by deploying an NVIDIA Corp. (NASDAQ:NVDA) DGX SuperPOD equipped with DGX Vera Rubin NVL72 systems.
The strategic deployment establishes the most robust and energy-efficient single-owned artificial intelligence infrastructure currently operating within the life sciences sector.
The move builds on the company’s broader AI strategy. In May, Bristol Myers signed a strategic agreement with Anthropic to deploy AI across its operations.
The partnership is designed to accelerate drug discovery and development by giving more than 30,000 employees access to institutional knowledge through Anthropic’s AI models.
AI Infrastructure Boost
The new Vera Rubin architecture marks a significant increase in computing power for Bristol Myers’ research teams.
According to the company, the platform delivers up to 10 times more performance per megawatt than the previous generation. That improvement allows researchers to run larger and more complex AI models while improving energy efficiency.
The deployment also extends a collaboration between Bristol Myers and NVIDIA that has spanned nearly three years.
The enhanced computing capacity will support research across several therapeutic areas, including oncology, cardiovascular disease, immunology, hematology and neuroscience.
Accelerating Drug Discovery
Using the new computing cluster and NVIDIA’s BioNeMo biological AI platform, Bristol Myers plans to train next-generation foundation models on decades of proprietary research data.
The company has also adopted a “Predict First” approach, in which AI-generated predictions help shape experiments before laboratory work begins.
Bristol Myers said AI now supports the design of every small-molecule drug program and most large-molecule development projects. The company expects the technology to improve decision-making from target identification through clinical proof of concept.
The announcement follows another AI-focused partnership unveiled in May. Tempus AI Inc. (NASDAQ:TEM) and Bristol Myers agreed to use AI, multimodal real-world data and advanced analytics to improve clinical trial design and increase the probability of technical and regulatory success across five initial oncology and neuroscience development programs.
BMY Price Action: Bristol-Myers Squibb shares were up 0.30% at $60.92 at the time of publication on Monday. The stock is approaching its 52-week high of $62.88, according to Benzinga Pro data.
Image via Shutterstock
Recent Comments